scholarly journals Neutrophil to lymphocyte ratio (NLR) impact on the survival and response duration of patients with metastatic castration resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA)

2016 ◽  
Vol 27 ◽  
pp. vi257
Author(s):  
A.B. Mansinho ◽  
D. Macedo ◽  
I.C. Fernandes ◽  
A. Quintela ◽  
L.A.M. Costa
Keyword(s):  
Prostate Cancer ◽  
Response Duration ◽  
Abiraterone Acetate ◽  
Neutrophil To Lymphocyte Ratio ◽  
Castration Resistant Prostate Cancer ◽  
Lymphocyte Ratio ◽  
Castration Resistant

scholarly journals A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Takashi Kawahara ◽  
Masashi Kato ◽  
Kenichi Tabata ◽  
Ippei Kojima ◽  
Hiroshi Yamada ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Prognostic Marker ◽  
Cancer Progression ◽  
Abiraterone Acetate ◽  
Neutrophil To Lymphocyte Ratio ◽  
Prostate Cancer Progression ◽  
Castration Resistant Prostate Cancer ◽  
Lymphocyte Ratio ◽  
Castration Resistant

Abstract Background Inflammatory cytokine markers, including the neutrophil-to-lymphocyte ratio (NLR), monocyte-lymphocyte ratio, and platelet-to-lymphocyte ratio, play important roles as prognostic markers in several solid malignancies, including prostate cancer. We previously reported the NLR as a poor prognostic marker in bladder cancer, upper-urothelial carcinoma, adrenocortical carcinoma, penile cancer, and prostate cancer. This study examined the importance of the NLR as a prognostic marker for castration-resistant prostate cancer (CRPC) patients who received abiraterone acetate or enzalutamide. Methods A total of 805 prostate cancer patients developed in CRPC status were enrolled in this study. Of these patients, 449 received abiraterone acetate (ABI; 188 cases) or enzalutamide (ENZ; 261 cases) treatment, and the pre-treatment NLR values of these patients were obtained. We investigated the prognosis in those with higher and lower NLR values. Results The median NLR was 2.90, and a receiver operating characteristics analysis suggested a candidate cut-off point of 3.02. The median overall survival (OS) was 17.3 months in the higher NLR group (≥3.02) and 27.3 months in the lower NLR group (< 3.02) (p < 0.0001). This trend was also observed in both the ABI and ENZ groups (ABI: 29.3 vs. 15.1 months; ENZ: NR vs. 19.5 months; p < 0.0001 and < 0.0001, respectively). A multivariate analysis revealed that a higher NLR was an independent risk factor. The NLR value was thus shown to be correlated with the prostate cancer progression. Conclusions A higher NLR was associated with a poorer OS for CRPC patients who received ABI or ENZ. The NLR was positively correlated with prostate cancer progression.

The docetaxel-abiraterone acetate sequence compared to the abiraterone acetate-docetaxel sequence in metastatic castration-resistant prostate cancer patients with a response to previous castration superior to 12 months.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 353-353
Author(s):  
Maxime Desle ◽  
Alexandre Derminne ◽  
Sarah Lejeune ◽  
Emmanuel Seront
Keyword(s):  
Prostate Cancer ◽  
Response Duration ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Sequence Group ◽  
Previous Response ◽  
Castration Resistant ◽  
Group A ◽  
Group B ◽  
Decision Choice

353 Background: With the approval of the multiple new life-prolonging treatments for men with metastatic castration-resistant prostate cancer (mCRPC), the optimal sequencing of chemotherapy and androgen-receptor (AR) targeting agents remains unclear. Although response duration to castration could influence decision choice for second hormonal therapies, we do not know whether chemotherapy efficacy could be similar to AR targeting agents such as abiraterone acetate (AA). Methods: A retrospective analysis of mCRPC patients treated at Jolimont Hospital is reported. Patients included were castration-resistant PC with a response to castration superior to 12 months. They were treated with sequential docetaxel and AA, in either order. The combined progression-free survival (combined PFS: PFS1 + PFS2) of AA followed by docetaxel is compared to the reverse sequence (docetaxel followed by AA). Baseline characteristics are reported prior to the start of the first agent in the sequence. Results: Forty-two patients who started treatment for mCRPC between January 2013 and February 2017 were identified: 22 were in the docetaxel-AA sequence (Group A) and 20 were in the AA-docetaxel sequence (Group B). The median duration of response to castration was 16 months in Group A and 18 months in Group B. Proportion of Gleason > 8 was higher in group A (60% vs 50%). Visceral or lymph node disease was more important in group A (35% vs 16%). Median pre-treatment PSA was similar in the two groups (27 and 30). In the group A, PFS1 was 9 months and PFS2 was 8 months, resulting in a combined PFS of 17 months (range 5 to 47months). In the group B, PFS1 was 8 months and PFS2 was 7 months, resulting in a combined PFS of 15 months (range 4 to 45 months). Conclusions: We do not observe differences in clinical outcomes based on alternative sequencing of AA and docetaxel in men with mCRPC with a previous response duration to castration longer than 12 months.

Sign in / Sign up

Export Citation Format

Share Document